These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 38892388)

  • 1. Targeting SHP2 Cryptic Allosteric Sites for Effective Cancer Therapy.
    Rehman AU; Zhao C; Wu Y; Zhu Q; Luo R
    Int J Mol Sci; 2024 Jun; 25(11):. PubMed ID: 38892388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting a cryptic allosteric site for selective inhibition of the oncogenic protein tyrosine phosphatase Shp2.
    Chio CM; Lim CS; Bishop AC
    Biochemistry; 2015 Jan; 54(2):497-504. PubMed ID: 25519989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in SHP2 tunnel allosteric inhibitors and bifunctional molecules.
    Guo Z; Duan Y; Sun K; Zheng T; Liu J; Xu S; Xu J
    Eur J Med Chem; 2024 Sep; 275():116579. PubMed ID: 38889611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.
    Chen YN; LaMarche MJ; Chan HM; Fekkes P; Garcia-Fortanet J; Acker MG; Antonakos B; Chen CH; Chen Z; Cooke VG; Dobson JR; Deng Z; Fei F; Firestone B; Fodor M; Fridrich C; Gao H; Grunenfelder D; Hao HX; Jacob J; Ho S; Hsiao K; Kang ZB; Karki R; Kato M; Larrow J; La Bonte LR; Lenoir F; Liu G; Liu S; Majumdar D; Meyer MJ; Palermo M; Perez L; Pu M; Price E; Quinn C; Shakya S; Shultz MD; Slisz J; Venkatesan K; Wang P; Warmuth M; Williams S; Yang G; Yuan J; Zhang JH; Zhu P; Ramsey T; Keen NJ; Sellers WR; Stams T; Fortin PD
    Nature; 2016 Jul; 535(7610):148-52. PubMed ID: 27362227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allosteric Inhibitors of SHP2 with Therapeutic Potential for Cancer Treatment.
    Xie J; Si X; Gu S; Wang M; Shen J; Li H; Shen J; Li D; Fang Y; Liu C; Zhu J
    J Med Chem; 2017 Dec; 60(24):10205-10219. PubMed ID: 29155585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis of small peptide compounds, molecular docking, and inhibitory activity evaluation against phosphatases PTP1B and SHP2.
    Kostrzewa T; Sahu KK; Gorska-Ponikowska M; Tuszynski JA; Kuban-Jankowska A
    Drug Des Devel Ther; 2018; 12():4139-4147. PubMed ID: 30584278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Scaffold-based novel SHP2 allosteric inhibitors design using Receptor-Ligand pharmacophore model, virtual screening and molecular dynamics.
    Jin WY; Ma Y; Li WY; Li HL; Wang RL
    Comput Biol Chem; 2018 Apr; 73():179-188. PubMed ID: 29494926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Probing the Dynamic Mechanism of Uncommon Allosteric Inhibitors Optimized to Enhance Drug Selectivity of SHP2 with Therapeutic Potential for Cancer Treatment.
    Farrokhzadeh A; Akher FB; Soliman MES
    Appl Biochem Biotechnol; 2019 May; 188(1):260-281. PubMed ID: 30430347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monobody Inhibitor Selective to the Phosphatase Domain of SHP2 and its Use as a Probe for Quantifying SHP2 Allosteric Regulation.
    Sha F; Kurosawa K; Glasser E; Ketavarapu G; Albazzaz S; Koide A; Koide S
    J Mol Biol; 2023 Apr; 435(8):168010. PubMed ID: 36806475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allosteric SHP2 inhibitors in cancer: Targeting the intersection of RAS, resistance, and the immune microenvironment.
    Kerr DL; Haderk F; Bivona TG
    Curr Opin Chem Biol; 2021 Jun; 62():1-12. PubMed ID: 33418513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual Allosteric Inhibition of SHP2 Phosphatase.
    Fodor M; Price E; Wang P; Lu H; Argintaru A; Chen Z; Glick M; Hao HX; Kato M; Koenig R; LaRochelle JR; Liu G; McNeill E; Majumdar D; Nishiguchi GA; Perez LB; Paris G; Quinn CM; Ramsey T; Sendzik M; Shultz MD; Williams SL; Stams T; Blacklow SC; Acker MG; LaMarche MJ
    ACS Chem Biol; 2018 Mar; 13(3):647-656. PubMed ID: 29304282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploring the cause of the dual allosteric targeted inhibition attaching to allosteric sites enhancing SHP2 inhibition.
    Yangchun M; WenYu Y; Liang Z; LiPeng L; JingWei W; WeiYa L; Shan D; Ying M; RunLing W
    Mol Divers; 2022 Jun; 26(3):1567-1580. PubMed ID: 34338914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploring the dynamic mechanism of allosteric drug SHP099 inhibiting SHP2
    Du S; Lu XH; Li WY; Li LP; Ma YC; Zhou L; Wu JW; Ma Y; Wang RL
    Mol Divers; 2021 Aug; 25(3):1873-1887. PubMed ID: 33392964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic potential of targeting SHP2 in human developmental disorders and cancers.
    Shen D; Chen W; Zhu J; Wu G; Shen R; Xi M; Sun H
    Eur J Med Chem; 2020 Mar; 190():112117. PubMed ID: 32061959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Off-target autophagy inhibition by SHP2 allosteric inhibitors contributes to their antitumor activity in RAS-driven cancers.
    Miao Y; Bai Y; Miao J; Murray AA; Lin J; Dong J; Qu Z; Zhang RY; Nguyen QD; Wang S; Yu J; Nguele Meke F; Zhang ZY
    J Clin Invest; 2024 Jun; 134(15):. PubMed ID: 38842946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allosteric modulation of SHP2: Quest from known to unknown.
    Wang N; Zhu S; Lv D; Wang Y; Khawar MB; Sun H
    Drug Dev Res; 2023 Nov; 84(7):1395-1410. PubMed ID: 37583266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent Advances of SHP2 Inhibitors in Cancer Therapy: Current Development and Clinical Application.
    Yuan X; Bu H; Zhou J; Yang CY; Zhang H
    J Med Chem; 2020 Oct; 63(20):11368-11396. PubMed ID: 32460492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural reorganization of SHP2 by oncogenic mutations and implications for oncoprotein resistance to allosteric inhibition.
    LaRochelle JR; Fodor M; Vemulapalli V; Mohseni M; Wang P; Stams T; LaMarche MJ; Chopra R; Acker MG; Blacklow SC
    Nat Commun; 2018 Oct; 9(1):4508. PubMed ID: 30375388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The loops of the N-SH2 binding cleft do not serve as allosteric switch in SHP2 activation.
    Anselmi M; Hub JS
    Proc Natl Acad Sci U S A; 2021 Apr; 118(17):. PubMed ID: 33888588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted Degradation of the Oncogenic Phosphatase SHP2.
    Vemulapalli V; Donovan KA; Seegar TCM; Rogers JM; Bae M; Lumpkin RJ; Cao R; Henke MT; Ray SS; Fischer ES; Cuny GD; Blacklow SC
    Biochemistry; 2021 Aug; 60(34):2593-2609. PubMed ID: 34411482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.